Articles On Kazia Therapeutics (ASX:KZA)

Unlike the majority of biotech players, Kazia Therapeutics has emphasised diversity in its clinical trials, so as to look at the potential of its lead drug paxalisib in a range of different treatment areas. The company currently has eight c...

ShareCafeEvening Report: 8 August, 2022 by Paul Sanger   After falling early in the session, the ASX managed to close in the green. Lithium stocks led the way, following comments from Albemarle that the lithium supply will remain tight for...

08 Aug 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Mesoblast (ASX:MSB), BHP Group (ASX:BHP) and Oz Minerals (ASX:OZL).

ShareCafeLunch Report: 8 August, 2022 by Paul Sanger   On the ASX this week we kick off the earnings season with 17 major ASX 200 companies reporting, including Suncorp (ASX:SUN) (today and more on its proposed bank sale to the ANZ), Comput...

ShareCafeStocks of the Hour: 8 August, 2022                    Kazia Therapeutics Limited (ASX:KZA) an oncology-focused drug development company, is pleased to announce the presentation of promising new data from an ongoing phase 1 cl...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Kazia Therapeutics (KZA) presents “promising” new data from an ongoing phase I clinical trial of its paxalisib product for the treatment of brain metastases The trial treated nine patients with paxalisib in combination with radiotherapy, w...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from an ongoing phase one clinical trial of its lead drug paxalisib in combination with radiotherapy for the treatment of brain metastases. Inter...

The ASX 200 will open slightly lower on Monday US non-farm payrolls surprise on the upside, but Wall Street finishes mixed on Friday Ahead this week, earnings season starts for ASX blue chips Local shares are set to open lower today. At 8...

ShareCafeThe Week that Was – August 1-5, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, h...

ShareCafeLunch Report: 5 August, 2022 by Tim McGowen   Gold stocks are stronger across the board as the price of gold reaches one month highs as the $US weakens and geopolitical tensions rise with China & Taiwan. The annual Diggers &amp...

ShareCafeGlobal Biotech Turnaround Looks to Be Underway Signs of life are emerging in the global biotech sector, after the longest and sharpest downturn in history that was so severe it left hundreds US companies trading below cash backing....

ShareCafeKazia: AGILE Hurdle Missed but Significant Value Remains Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download...

The ASX 200 is up 0.6%, the XEC small caps index is down 0.8%  Tomorrow is RBA day, Wednesday is OPEC+ arvo We all should’ve bought into CBE last week, dammit    The local sharemarket is creeping quietly higher on Wednesday, with the reso...

In case you were wondering, it is the Kazia Therapeutics Ltd (ASX: KZA) share price that’s crashing heavily today. After opening at 35 cents for the day, shares in the oncology-focused drug development company are continuing to freefall....

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

SYDNEY, July 12, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB consists of fou...

Kazia Therapeutics (ASX: KZA) has launched a new scientific advisory board (SAB) consisting of “world-leading experts” in developing therapies for brain cancer. Sydney-based oncology-focused Kazia will lean on SAB’s guidance in progressing...

ShareCafeEvening Report: 6 July, 2022 by Melissa Darmawan   Australia’s trade surplus hit a record high in May, driven by higher prices of coal, while imports suggested consumer demand is strong as the country continues to open. The surplu...

ShareCafeLunch Report: 7 July, 2022 by Melissa Darmawan   Australian stocks have rebounded, helped by Chalice Mining’s latest discovery, which has helped to lift the material sector. Gains in consumer staples and discretionary stocks have o...

07 Jul 2022 - A snapshot of the stocks on the move, featuring Elsight (ASX:ELS), Kazia Therapeutics (ASX:KZA), and Chalice Mining (ASX:CHN).

Kazia Therapeutics’ (ASX: KZA) lead drug candidate paxalisib has been awarded rare paediatric disease designation (RPDD) for the treatment of a highly-aggressive childhood brain cancer known as atypical rhabdoid teratoid tumour (AT/RT). The...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

SYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pedi...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market for biotech companies. A Phase I study of...

Kazia Therapeutics (ASX:KZA) has announced that the US FDA has granted Orphan Drug Designation to its paxalisib for the treatment of atypical rhabdoid/teratoid tumours.

SYDNEY, June 17, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan D...

The US FDA has awarded Kazia Therapeutics (KZA) Orphan Drug Designation (ODD) for its paxalisib drug to treat a rare type of childhood brain cancer The designation is for paxalisib to treat atypical rhabdoid/teratoid tumours which is a rar...

Highlights Kazia Therapeutics’ lead drug candidate, Paxalisib, secures ODD from the FDA for the treatment of a kind of brain cancer. Kazia will save over US$3 million in fees related to a future regulatory filing in atypical rhabdoid/t...

Kazia gets designation approval from US FDA Lumos signs contract to make at-home screening test product Trajan acquires US-based company, in trading halt Oncology company Kazia Therapeutics (ASX:KZA) says its lead drug paxalisib has been...

Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive childhood brain cancer. The ODD is specif...

ShareCafeEvening Report: 14 June, 2022 by Paul Sanger   The Australian sharemarket has suffered its worst losses in over two years, obliterating $82bn of market capitalisation off the ASX 200. At the closing bell, the S&P/ASX 200 plunge...

“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers. The company is presenting the data via two presentations this week at the 20th Internat...

14 Jun 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Westgold Resources (ASX:WGX) & Lake Resources (ASX:LKE).

Kazia Therapeutics (KZA) sees new data presented for its brain cancer drug, Paxalisib, highlighting its use in two forms of childhood brain cancer The data has been presented in two poster presentations at the International Symposium on Pe...

SYDNEY, June 13, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its drug paxalisib in patients with brain metastases to include those starting from breast cancer. The genomically-guided study, led by the US-b...

SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metasta...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

SYDNEY, June 3, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patien...

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe. GBM AGILE is a global, academic-led study designed to ident...

SYDNEY, May 31, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment t...

SYDNEY, May 23, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferen...

SYDNEY, May 17, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks ‘DIPG Awareness Day’ by recognizing the tireless work of global researchers in this d...

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

The deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed life science plays looking a tad sickly, too. Arguably, many of them were overvalued in the first place. But in many cases the companies ar...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Oncology-focused drug development company Kazia Therapeutics (KZA) establishes an “at-the-market” equity program, with Oppenheimer & Co acting as sales agent Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million (...